Suppliers / Yabao Pharmaceutical Group

Yabao Pharmaceutical Group

China 410 employees Updated 9 July 2026

Yabao Pharmaceutical Group is an API manufacturer based in China. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 24 January 2025 as NAI.

7
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 24 January 2025 NAI US FDA
  • 9 September 2016 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3007426459

What they file, and where

Molecule Regulators Docs
Dabigatran Etexilate US FDA 1
Dimethyl Fumarate US FDA 1
Gefitinib US FDA 1
Iron Sucrose US FDA 1
Promestriene US FDA 1
Sorafenib US FDA 1
Tofacitinib US FDA 1

Also appears on these molecule pages

Dabigatran Etexilate API Dimethyl API Gefitinib API Sorafenib API Tofacitinib API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Yabao Pharmaceutical Group

Does Yabao Pharmaceutical Group hold a US DMF or a CEP?
Yabao Pharmaceutical Group holds 7 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Yabao Pharmaceutical Group FDA-registered?
One site operated by Yabao Pharmaceutical Group carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Yabao Pharmaceutical Group's last inspection go?
The most recent inspection on record closed on 24 January 2025 as NAI (No Action Indicated: nothing objectionable was found). 2 inspections are on file.
Where does Yabao Pharmaceutical Group manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Yabao Pharmaceutical Group make?
7 molecules are on record against Yabao Pharmaceutical Group, including Dabigatran Etexilate, Dimethyl Fumarate, Gefitinib and Iron Sucrose. Each links through to that molecule's full manufacturer list.
Which regulators recognise Yabao Pharmaceutical Group's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Yabao Pharmaceutical Group?

Ask Fred what the record holds on Yabao Pharmaceutical Group, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Open risk flags

  • The most recent inspection outcome was NAI, on 24 January 2025.

Comparable suppliers

MSN Laboratories shares 3 molecules Apitoria Pharma shares 3 molecules Hetero shares 3 molecules Dr Reddy's Laboratories shares 3 molecules Alivus Life Sciences shares 3 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates